Transfusion Transmitted Infectious Diseases


evaluate and advance safety of blood transfusion by analysing Transfusion Transmitted Infectious Diseases, coordinating international studies and publishing scientific reports

Following blood transfusion, there is a risk of transfusion-transmitted infectious diseases (TTID), despite current advanced screening technologies. Infectious agents involved are very diverse and include hepatitis B (HBV), hepatitis C (HCV), human immunodeficiency (HIV-1/2), human T-cell lymphotropic (HTLV-I/II), Cytomegalo- (CMV), Parvo- B19, West Nile (WNV) and Dengue viruses. Trypanosomiasis, malaria, and Transmissible Spongiform Encephalopathy (TSE) also belong to TTID. TTID can be reduced by donor exclusion, screening for serological infection markers or nucleic acid testing (NAT) by viral gene amplification. Despite this, blood-borne infectious agents are transmitted through transfusion of infected blood donated by apparently healthy and asymptomatic blood donors.


We are responsible for evaluation and promotion of ways to increase blood safety in order to reduce the frequency of TTID. Our members participate in the following subgroups:

1) Bacteria

2) Parasites

3) Virology

4) Prions/Transmissible spongiform encephalopathy (TSE)

5) Surveillance, Risk Assessment & Policy (SRAP)

The latest findings based on literature reviews as well as member's experiences are also discussed. And we bring together scientific experts, company representatives and members from leading institutions and regulatory authorities.

Our Chairperson is Michael Busch.




We participate in subgroups and attend 1-2 day WP meetings linked to ISBT Congresses. Our subgroups develop and execute various surveys and laboratory experiments, analyse data with the intention to publish. Our subgroups discuss issues by conference call and in person. We sponsor Travel Awards and are launching a mentoring and training program for early/mid-career investigators, particularly from resource-limited countries.

Joining the WP

Applicants for membership must have a documented interest in TTID and preferably be involved in TTID surveillance or research. Equal representation of all world regions is a priority; we currently have over 90 members from ~30 different countries.

Employees from pharmaceutical companies are only able to join as Corporate Sponsors.

Interested in joining the TTID WP? Please email the ISBT Office or our Chairperson. 





Some of the content is only accessible for ISBT-members. To join us, click here.

General Presentations


  1. Establishment of the first international repository for transfusion-relevant bacteria reference strains: ISBT working party transfusion-transmitted infectious diseases (WP-TTID), subgroup on bacteria Störmer M, Arroyo A, Brachert J, Carrero H, Devine D, Epstein JS, Gabriel C, Gelber C, Goodrich R, Hanschmann KM, Heath DG, Jacobs MR, Keil S, de Korte D, Lambrecht B, Lee CK, Marcelis J, Marschner S, McDonald C, McGuane S, McKee M, Müller TH, Muthivhi Vox Sang. 2012 Jan;102(1):22-31. doi: 10.1111/j.1423-0410.2011.01510.x.
  2. The international experience of bacterial screen testing of platelet components with an automated microbial detection system: a need for consensus testing and reporting guidelines Benjamin RJ1, McDonald CP2; ISBT Transfusion Transmitted Infectious Disease Bacterial Workgroup Transfus Med Rev. 2014 Apr;28(2):61-71.
  3. Comparison of seven hepatitis B virus (HBV) nucleic acid testing (NAT) assays in selected samples with discrepant HBV marker results from United States blood donors. Enjalbert F, Krysztof D, Candotti D, Allain JP, Stramer S. Transfusion 2014 Oct;54(10):2485-95.
  4. Zika virus: a new challenge for blood transfusion D Musso, SL Stramer, MP Busch The Lancet, 2016
  5. Survey for bacterial testing of platelet components in Latin America Ramirez-Arcos S, McDonald C; Benjamin R ISBT Science Series, 2017 May 17
  6. Development of a web‐based application and multicountry analysis framework for assessing interdicted infections and cost‐utility of screening donated blood for HIV, HCV and HBV B. Custer M. P. Janssen G. Hubben M. Vermeulen M. van Hulst Vox Sang 2017 June, 112, 526–534,
  7. Enlargement of the WHO international repository for platelet transfusion‐relevant bacteria reference strains E. Spindler‐Raffel R. J. Benjamin C. P. McDonald S. Ramirez‐Arcos K. Aplin I. Bekeredjian‐Ding D. de Korte C. Gabriel B. Gathof K.‐M. Hanschmann K. Hourfar C. Ingram M. R. Jacobs S. D. Keil Y. Kou B. Lambrecht J. Marcelis Z. Mukhtar Vox Sang 2017 Sept, 112, 713–722,
  8. A pilot serosurvey of Babesia microti in Chinese blood donors. Bloch EM, Yang Y, He M, Tonnetti L, Liu Y, Wang J, Guo Y, Li H, Leiby DA, Shan H; ISBT TTID Working Party Parasite Subgroup Vox Sang. 2018 Mar 26. doi: 10.1111/vox.12648

Cost Utility Analysis Webtool for HIV, HBV and HCV

Access the webtool here.


I TRY IT Workshop in Dubai

Participants of the I TRY IT programme were invited to the 34th International Congress of the ISBT in Dubai to attend one-on-one mentoring sessions and to receive training on peer reviewing. 

To read the entire report please login or become an ISBT member.

Watch the webcast "Assessing the risk of new emerging infections"

Follow this link to visit ISBT Education and watch the webcast of Brian Custer. The talk was recorded at the 25th Regional Congress of the ISBT in Kuala Lumpur. 



Michael Busch

Michael Busch


Blood Systems Research Institute
San Francisco, USA

All subgroups have different coordinators, contact details are shown below.